Biodesp

Description

BiodespDMNF is a pharmaceutical compound characterized by its specific chemical properties. The molecular weight and chemical formula are not provided in the extracted data. The compound is formulated for use in a specific dosage form, although details regarding the form and appearance are also not included. Further information regarding inactive ingredients and other relevant characteristics is necessary for a comprehensive understanding of BiodespDMNF's profile.

Uses and Indications

This drug is indicated for the temporary relief of symptoms associated with the common cold, hay fever (allergic rhinitis), and other upper respiratory allergies. Specifically, it alleviates cough resulting from minor throat and bronchial irritation, aids in loosening phlegm (mucus) and thinning bronchial secretions to facilitate drainage of the bronchial tubes, and addresses nasal congestion by reducing swelling of the nasal passages.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The recommended dosage for adults and children aged 12 years and older is 2 teaspoonfuls (10 mL) administered every 4 hours. The maximum allowable dosage is 6 doses within a 24-hour period, unless otherwise directed by a healthcare professional.

For children aged 6 to under 12 years, the dosage is 1 teaspoonful (5 mL) every 4 hours, adhering to the same maximum of 6 doses in 24 hours.

In children under 6 years of age, the dosage is 1/2 teaspoonful (2.5 mL) every 4 hours; however, it is essential to consult a healthcare provider before administration in this age group.

Healthcare professionals should ensure that patients do not exceed the recommended dosage and advise them to seek medical guidance if symptoms persist or worsen.

Contraindications

There are no contraindications associated with the use of this product. It is not classified as a controlled substance, and there are no identified risks of abuse, misuse, or dependence.

Warnings and Precautions

Patients should not exceed the recommended dosage of this product. A persistent cough may indicate a serious underlying condition; therefore, if a cough persists for more than one week, recurs, or is accompanied by fever, rash, or a persistent headache, it is imperative to consult a healthcare professional.

This product is contraindicated for individuals currently taking a prescription monoamine oxidase inhibitor (MAOI) or for two weeks following the cessation of an MAOI. MAOIs are commonly prescribed for depression and other psychiatric or emotional conditions. If there is uncertainty regarding the presence of an MAOI in a prescription medication, patients should seek guidance from a healthcare provider or pharmacist prior to use.

General precautions should be observed. Patients are advised to consult a healthcare professional before using this product if they have any of the following conditions: a persistent or chronic cough associated with smoking, asthma, chronic bronchitis, or emphysema, particularly if accompanied by excessive phlegm; high blood pressure; heart disease; thyroid disease; diabetes; or difficulty urinating due to prostate gland enlargement, unless directed otherwise by a physician. Additionally, individuals taking sedatives or tranquilizers should seek medical advice before use.

Patients should discontinue use and contact a healthcare provider if they experience nervousness, dizziness, or sleeplessness. Furthermore, if symptoms do not improve within seven days or are accompanied by fever, medical consultation is necessary.

In the event of an accidental overdose, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

Side Effects

Patients may experience a range of adverse reactions associated with the use of this product. It is important to monitor for serious symptoms, particularly a persistent cough, which may indicate a serious underlying condition. If a cough persists for more than one week, recurs, or is accompanied by fever, rash, or a persistent headache, patients should consult a healthcare professional.

Common adverse reactions may include nervousness, dizziness, or sleeplessness. If any of these symptoms occur, patients are advised to stop use and seek medical advice. Additionally, if symptoms do not improve within seven days or are accompanied by fever, it is recommended that patients consult a doctor.

Patients should be cautious and seek medical advice before using this product if they have a persistent or chronic cough, such as that associated with smoking, asthma, chronic bronchitis, or emphysema, especially if the cough is accompanied by excessive phlegm. Other conditions that warrant consultation include high blood pressure, heart disease, thyroid disease, diabetes, and difficulty in urination due to prostate enlargement.

Furthermore, patients should not use this product if they are currently taking a prescription monoamine oxidase inhibitor (MAOI) or have taken one within the past two weeks. It is also advisable to consult a healthcare provider before use if patients are taking sedatives or tranquilizers.

Drug Interactions

The concomitant use of this product with prescription monoamine oxidase inhibitors (MAOIs) is contraindicated. Patients should not use this product while taking MAOIs or for a period of two weeks following the discontinuation of MAOI therapy. It is essential for patients to consult with a healthcare professional if they are uncertain whether their prescription medication contains an MAOI.

Additionally, caution is advised when considering the use of this product in conjunction with sedatives or tranquilizers. Patients are encouraged to seek medical advice prior to use if they are currently taking these types of medications to ensure safety and appropriate management of potential interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Biodesp (dextromethorphan hbr, guaifenesin, phenylephrine hcl). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 6 to under 12 years may be administered 1 teaspoonful (5 mL) every 4 hours. For children under 6 years of age, the recommended dosage is 1/2 teaspoonful (2.5 mL) every 4 hours; however, it is advised to consult a doctor before use in this age group.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. It is important to assess the potential risks and benefits associated with the use of this drug during pregnancy and lactation. Healthcare providers should evaluate the individual circumstances of each patient to ensure the safety of both the mother and the fetus.

Lactation

Lactating mothers are advised to consult a healthcare professional prior to using this medication. There is limited information available regarding the excretion of this drug in human breast milk and its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have not been specifically addressed in terms of dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to individuals with reduced kidney function, as the lack of data necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in these patients to ensure safety and efficacy.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In cases of overdosage, it is imperative that healthcare professionals adhere to the recommended dosage guidelines to prevent adverse effects. Exceeding the recommended dosage may lead to serious health complications.

Symptoms of Overdosage While specific symptoms of overdosage may vary depending on the substance involved, it is crucial for healthcare providers to monitor patients closely for any signs of toxicity or adverse reactions. Common symptoms may include, but are not limited to, gastrointestinal disturbances, neurological changes, and cardiovascular irregularities.

Management Procedures In the event of suspected overdosage, immediate medical attention is required. Healthcare professionals should initiate supportive care and symptomatic treatment as necessary. It is advisable to contact a poison control center or consult relevant clinical guidelines for specific management recommendations tailored to the substance involved.

Prompt recognition and intervention are essential to mitigate the risks associated with overdosage. Continuous monitoring and assessment of the patient's condition will guide further therapeutic decisions.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's safety profile in nonclinical settings.

Postmarketing Experience

Postmarketing experience has identified the following adverse reactions reported voluntarily or through surveillance programs: nervousness, dizziness, and sleeplessness. These events have been documented in the context of routine pharmacovigilance activities.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of the reach of children to prevent accidental ingestion. It is important for patients to understand the potential risks associated with this medication and to take necessary precautions to ensure safety.

In the event of an accidental overdose, healthcare providers should instruct patients to seek medical help or contact a Poison Control Center immediately. Emphasizing the importance of prompt action in such situations can help mitigate potential health risks.

Storage and Handling

The product is supplied in a container that must be kept tightly closed to maintain integrity. It should be stored at a temperature range of 20°C to 25°C (68°F to 77°F), with permissible excursions between 15°C to 30°C (59°F to 86°F). It is essential to protect the product from light to ensure its stability. Additionally, the product should be discarded after opening to prevent any potential degradation or contamination.

Additional Clinical Information

The medication is administered orally, with a recommended dosage of every 4 hours, not to exceed 6 doses within a 24-hour period unless directed otherwise by a healthcare professional. Clinicians should advise patients to keep the medication out of the reach of children and to seek immediate medical assistance or contact a Poison Control Center in the event of an accidental overdose. Additionally, patients who are pregnant or breastfeeding should consult a doctor prior to use.

Drug Information (PDF)

This file contains official product information for Biodesp, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)